XML 38 R24.htm IDEA: XBRL DOCUMENT
v3.26.1

Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Accounting Policies [Abstract] |
Schedule of Cash and Cash Equivalents | The following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total of the same such amounts shown in the consolidated statements of cash flows (in thousands): Schedule of Cash and Cash Equivalents
|  | December 31, 2025 |  |  | December 31, 2024 |
Cash |  | $ | 5,600 |  |  | $ | 9,591 |
Restricted cash included within prepaid expenses and other current assets |  |  | 100 |  |  |  | 100 |
Restricted cash included within other noncurrent assets |  |  | 119 |  |  |  | 118 |
Total cash and restricted cash as shown in the consolidated statements of cash flows |  | $ | 5,819 |  |  | $ | 9,809 |
Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive | As the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because including them would have been antidilutive (in thousands): Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive
|  | 2025 |  |  | 2024 |
|  | Year Ended December 31, |
|  | 2025 |  |  | 2024 |
Warrants for common stock |  |  | 5,026 |  |  |  | 911 |
Employee stock options |  |  | 278 |  |  |  | 77 |
Earnout shares |  |  | 150 |  |  |  | 150 |
Restricted stock units |  |  | — |  |  |  | 2 |
Contingently issuable warrants(1) |  |  | — |  |  |  | — |
Total common stock equivalents |  |  | 5,454 |  |  |  | 1,140 |
(1) | The contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December 31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved in full and there were no contingently issuable warrants outstanding.
Schedule of Operating Segment | The following table presents selected financial information with respect to the Company’s single operating segment for the year ended December 31, 2025 and 2024: Schedule of Operating Segment
|  | 2025 |  |  | 2024 |
|  | Year Ended December 31, |
|  | 2025 |  |  | 2024 |
OPERATING EXPENSES |  |  |  |  |  |  |  |
Salaries and benefits |  | $ | (9,561 | ) |  | $ | (10,249 | )
Insurance |  |  | (801 | ) |  |  | (1,442 | )
Legal |  |  | (1,324 | ) |  |  | (1,951 | )
Consulting |  |  | (2,059 | ) |  |  | (1,578 | )
Rent and maintenance |  |  | (2,358 | ) |  |  | (2,136 | )
Clinical & research and development |  |  | (1,760 | ) |  |  | (1,353 | )
Depreciation expense |  |  | (386 | ) |  |  | (402 | )
Change in fair value of other liabilities and derivatives |  |  | 2 |  |  |  | 324 |
Other segment items (1) |  |  | (1,801 | ) |  |  | (3,408 | )
Income tax provision |  |  | (15 | ) |  |  | (14 | )
NET LOSS |  | $ | (20,063 | ) |  | $ | (22,209 | )
| (1) | Other segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in Nova Cell, and other income, net.

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cash, cash equivalent, and investment. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration